The Pediatric AIDS Clinical Trials Group (PACTG) remains the preeminent organization in the world for evaluating treatments for HIV-infected children and adolescents, and for developing new approaches for the interruption of mother-to-infant transmission. It has set the standards of care for children infected with HIV and for the interruption of vertical transmission, and for research on HIV pathogenesis in infants and children. The PACTG is a multi-center, multidisciplinary investigative group. This cooperative agreement concerns the PACTG Coordinating and Operations Center (CORC), which include support for the Group Leader, the Executive Committee, other standing committees, a Community Constituency Group, the Operations Center, and the Core Laboratories. Associated with the CORC, under separate applications, are 18 Pediatric AIDS Clinical Trials Units and a Statistical and Data Management Center. The Group will be managed by an Executive Committee, which will oversee an integrated research agenda developed by five Research Agenda Committees (Perinatal Transmission, Primary Therapy, Complications of HIV, Immunology/Immune-Based Therapy Vaccine, and Adolescent), three Scientific Committees (Virology, Immunology, and Pharmacology), and three Resource Committees (Community Constituency Group, Pediatric Site Resource Committee, and the International Committee). The scientific agenda of the PACTG encompasses the critical issues that impact mother-to-infant transmission and treatment of HIV-infected children and adolescents. The four primary goals of the PACTG's scientific agenda are (1) to optimize strategies to maintain or improve mother-to-infant transmission at <2% without long-term toxicity to exposed infants or treated pregnant women in the U.S.; (2) to enable >90% of children perinatally infected with HIV to achieve normal growth and development, and >20 years survival in the U.S. ; (3) to determine the pharmacologic, immunologic and behavioral characteristics unique to adolescents and to develop improved strategies for therapeutic intervention that will enable adherence of >75% of youth receiving antiretroviral therapy; and (4) to use both domestic and international sites, to develop simpler and more effective treatment interventions that will prolong survival of HIV-infected children while retaining optimal quality of life.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI041089-08
Application #
6894702
Study Section
Special Emphasis Panel (ZAI1-PSS-A (J1))
Program Officer
Germuga, Donna E
Project Start
1997-03-01
Project End
2007-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
8
Fiscal Year
2005
Total Cost
$13,579,521
Indirect Cost
Name
Social and Scientific Systems, Inc.
Department
Type
DUNS #
091340943
City
Silver Spring
State
MD
Country
United States
Zip Code
20910
Aweeka, F T; Hu, C; Huang, L et al. (2015) Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med 16:176-83
Olson, Scott C; Ngo-Giang-Huong, Nicole; Beck, Ingrid et al. (2015) Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission. AIDS 29:1467-71
Qin, Min; Brummel, Sean; Singh, Kumud K et al. (2014) Associations of host genetic variants on CD4? lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children. Pediatr Infect Dis J 33:946-52
Buckoreelall, Kajal; Cressey, Tim R; King, Jennifer R (2012) Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 51:639-59
Saitoh, Akihiko; Capparelli, Edmund; Aweeka, Francesca et al. (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285-9
Huang, Yangxin; Wu, Hulin; Acosta, Edward P (2010) Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors. Biom J 52:470-86
Aldrovandi, Grace M; Lindsey, Jane C; Jacobson, Denise L et al. (2009) Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 23:661-72
Aldrovandi, Grace M; Chu, Clara; Shearer, William T et al. (2009) Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics 124:e1189-97
Valente, Thomas W; Zogg, Jennifer B; Christensen, Shawna et al. (2009) Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr 52:514-23
Melvin, Ann J; Kang, Minhee; Hitti, Jane et al. (2008) Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. Antivir Ther 13:349-55

Showing the most recent 10 out of 84 publications